The Skin Microbiome and Its Role in Psoriasis: A Review.
gut microbiome
molecular precision medicines
new therapies
next generation treatments
psoriasis
skin microbiome
Journal
Psoriasis (Auckland, N.Z.)
ISSN: 2230-326X
Titre abrégé: Psoriasis (Auckl)
Pays: New Zealand
ID NLM: 101709086
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
07
2023
accepted:
18
10
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
The skin microbiome is made of various microorganisms, most of which have the function of protecting individuals from harmful pathogens, and they are involved in innate and adaptive immune responses. The skin acts as a physical and immunological barrier against external stimuli, including pathogens and physical damage. Changes in the composition of the skin microbiome can trigger inflammatory processes leading to inflammatory skin diseases in susceptible individuals. Psoriasis (PsO) is a chronic inflammatory disease with a multifactorial etiology, where breakdown of immune tolerance to cutaneous microorganisms is implicated in its pathogenesis. Dysregulation of the microbiome due to genetic and environmental factors plays a significant role in the development of psoriatic disease. Dermatologic conditions such as atopic dermatitis, acne, psoriasis, and rosacea have been associated with intestinal dysbiosis. The skin microbiota composition is crucial for the development of appropriate immune responses, and alterations in the skin microbiome can contribute to changes in physiology and susceptibility to skin diseases or inflammatory conditions. Understanding the microbial settlement of the skin and the network of interactions that occur throughout life is essential for comprehending the pathogenesis of skin diseases and developing innovative treatments. With this article we tried to explore the relationship between the human microbiome and psoriatic disease, shedding light on the functions of the microbiome and the inflammatory disease processes to identify additional therapeutic targets. This review aims to highlight the relationship between skin and gut microbiome functions and inflammatory processes in skin psoriasis and psoriatic arthritis (PsA). The goal is to facilitate future studies on the skin microbiome to identify potential novel therapies for patients with psoriatic disease.
Identifiants
pubmed: 37908308
doi: 10.2147/PTT.S328439
pii: 328439
pmc: PMC10614657
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
71-78Informations de copyright
© 2023 Celoria et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Br J Dermatol. 2020 Jan;182(1):39-46
pubmed: 31049923
BMC Microbiol. 2021 Mar 8;21(1):78
pubmed: 33685393
Nat Commun. 2019 Oct 16;10(1):4703
pubmed: 31619666
Science. 2009 May 29;324(5931):1190-2
pubmed: 19478181
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34769005
Br J Dermatol. 2022 Nov;187(5):684-691
pubmed: 35764530
Cell Death Dis. 2022 Jan 24;13(1):81
pubmed: 35075118
Autoimmun Rev. 2014 Apr-May;13(4-5):490-5
pubmed: 24434359
Genome Biol. 2014 May 07;15(5):R66
pubmed: 24887286
Dermatol Reports. 2021 Dec 28;14(1):9188
pubmed: 35371420
mBio. 2019 Jul 2;10(4):
pubmed: 31266865
J Eur Acad Dermatol Venereol. 2020 Mar;34(3):455-464
pubmed: 31520544
Plast Reconstr Surg. 2021 Jan 1;147(1S-2):50S-61S
pubmed: 33347075
PLoS One. 2008 Jul 23;3(7):e2719
pubmed: 18648509
J Am Acad Dermatol. 2011 Jul;65(1):84-91
pubmed: 21458106
Acta Derm Venereol. 2020 Sep 30;100(16):adv00273
pubmed: 32852562
J Am Acad Dermatol. 2020 Apr;82(4):955-961
pubmed: 31228520
J Am Acad Dermatol. 2005 Jul;53(1):67-72
pubmed: 15965423
Microbiome. 2013 Dec 23;1(1):31
pubmed: 24451201
J Dtsch Dermatol Ges. 2011 Jan;9(1):21-5
pubmed: 21059171
Eur J Dermatol. 2006 Sep-Oct;16(5):511-7
pubmed: 17101471
Am J Clin Dermatol. 2020 Sep;21(Suppl 1):12-17
pubmed: 32910437
Arch Dermatol. 1982 May;118(5):322-5
pubmed: 6211147
Annu Rev Microbiol. 1988;42:441-64
pubmed: 3144238
J Formos Med Assoc. 2019 Mar;118 Suppl 1:S23-S31
pubmed: 30181015
Curr Top Microbiol Immunol. 2007;314:113-41
pubmed: 17593659
Science. 2014 Nov 21;346(6212):954-9
pubmed: 25414304
J Invest Dermatol. 2021 Jul;141(7):1630-1632
pubmed: 34167722
Cell. 2016 May 5;165(4):854-66
pubmed: 27153496
J Dermatol Sci. 2015 Oct;80(1):3-12
pubmed: 26278471
Dermatol Ther (Heidelb). 2023 Oct;13(10):2331-2343
pubmed: 37653234
Arch Dermatol Res. 2012 Jan;304(1):15-22
pubmed: 22065152
Nat Rev Microbiol. 2011 Apr;9(4):244-53
pubmed: 21407241
Science. 2009 Dec 18;326(5960):1694-7
pubmed: 19892944
Genome Res. 2015 Oct;25(10):1514-20
pubmed: 26430162
Equine Vet J. 2017 May;49(3):345-351
pubmed: 27338788
Microbiome. 2018 Sep 5;6(1):154
pubmed: 30185226
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17994-9
pubmed: 19004758
Front Microbiol. 2020 Dec 15;11:589726
pubmed: 33384669
Eur J Dermatol. 2008 Sep-Oct;18(5):504-11
pubmed: 18693151
Arthritis Rheumatol. 2015 Jan;67(1):128-39
pubmed: 25319745
Clin Mol Allergy. 2016 Jan 25;14:2
pubmed: 26811697
Nature. 2014 Oct 2;514(7520):59-64
pubmed: 25279917